Thematic area:
Advanced Wearables
Product:
A non-invasive wearable delivering personalised neuromodulation therapy to stimulate retinal cells and slow neurodegeneration in glaucoma patients. Powered by machine learning guided stimulation algorithms.
Market:
Initially targets ophthalmology clinics (~$120M annual market), then expands to a home-use device for ~0.9M eligible patients, representing a $2.7B/year opportunity.
Fit:
Current glaucoma treatments only regulate intraocular pressure; none address retinal neurodegeneration. NeuroVision fills this critical gap with strong clinical endorsement and disruptive potential.
